Franck Bourdeaut

List of Publications by Year
in descending order

96 papers	6,124 citations	109321 35 h-index	74163 75 g-index
112 all docs	112 docs citations	112 times ranked	8338 citing authors

#	Article	IF	Citations
1	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
2	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
3	Germline Mutations of the Pairedâ€“Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma. American Journal of Human Genetics, 2004, 74, 761-764.	6.2	288
4	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
5	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	21.4	252
6	SWI/SNF Chromatin Remodeling and Human Malignancies. Annual Review of Pathology: Mechanisms of Disease, 2015, 10, 145-171.	22.4	242
7	Frequent hSNF5/INI1 Germline Mutations in Patients with Rhabdoid Tumor. Clinical Cancer Research, 2011, 17, 31-38.	7.0	191
8	Atypical teratoid/rhabdoid tumorsâ€”current concepts, advances in biology, and potential future therapies. Neuro-Oncology, 2016, 18, 764-778.	1.2	185
9	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	30.7	172
10	Retinoblastoma and Neuroblastoma Predisposition and Surveillance. Clinical Cancer Research, 2017, 23, e98-e106.	7.0	166
11	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
12	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3122-3130.	1.6	142
13	Cancer Surveillance in Gorlin Syndrome and Rhabdoid Tumor Predisposition Syndrome. Clinical Cancer Research, 2017, 23, e62-e67.	7.0	139
14	A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clinical Cancer Research, 2017, 23, 2433-2441.	7.0	134
15	Same-day genomic and epigenomic diagnosis of brain tumors using real-time nanopore sequencing. Acta Neuropathologica, 2017, 134, 691-703.	7.7	131
16	hSNF5/INI1-deficient tumours and rhabdoid tumours are convergent but not fully overlapping entities. Journal of Pathology, 2007, 211, 323-330.	4.5	120
17	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1â€“2 study. Lancet Oncology, The, 2020, 21, 134-144.	10.7	103
18	Clinicopathologic prognostic factors in childhood atypical teratoid and rhabdoid tumor of the central nervous system. Cancer, 2012, 118, 3812-3821.	4.1	101

#	Article	IF	Citations
19	Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors. Cancer Cell, 2019, 36, 597-612.e8.	16.8	100
20	Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncology, The, 2013, 14, e329-e336.	10.7	94
21	The occurrence of intracranial rhabdoid tumours in mice depends on temporal control of Smarcb1 inactivation. Nature Communications, 2016, 7, 10421.	12.8	92
22	Extraâ€renal nonâ€cerebral rhabdoid tumours. Pediatric Blood and Cancer, 2008, 51, 363-368.	1.5	80
23	Diagnosis of Constitutional Mismatch Repair-Deficiency Syndrome Based on Microsatellite Instability and Lymphocyte Tolerance to Methylating Agents. Gastroenterology, 2015, 149, 1017-1029.e3.	1.3	76
24	Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Cancer Letters, 2005, 228, 51-58.	7.2	63
25	PHOX2B Immunolabeling. American Journal of Surgical Pathology, 2012, 36, 1141-1149.	3.7	55
26	Rhabdomyosarcomas in children with neurofibromatosis type I: A national historical cohort. Pediatric Blood and Cancer, 2015, 62, 1733-1738.	1.5	55
27	Predisposition to cancer in children and adolescents. The Lancet Child and Adolescent Health, 2021, 5, 142-154.	5.6	53
28	Renal Medullary Carcinoma: Establishing Standards in Practice. Journal of Oncology Practice, 2017, 13, 414-421.	2.5	52
29	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. Cancer Cell, 2018, 33, 435-449.e6.	16.8	52
30	Atypical teratoid/rhabdoid tumors (ATRTs) with SMARCA4 mutation are molecularly distinct from SMARCB1-deficient cases. Acta Neuropathologica, 2021, 141, 291-301.	7.7	47
31	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
32	Embryonal tumors with multilayered rosettes in children: the SFCE experience. Child's Nervous System, 2016, 32, 299-305.	1.1	46
33	ETMR-like infantile cerebellar embryonal tumors in the extended morphologic spectrum of DICER1-related tumors. Acta Neuropathologica, 2019, 137, 175-177.	7.7	43
34	Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy. Journal of Medical Genetics, 2019, 56, 53-62.	3.2	40
35	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. European Journal of Human Genetics, 2012, 20, 291-297.	2.8	38
36	Embryonal tumor with multilayered rosettes: Diagnostic tools update and review of the literature. , 2014, 33, 15-22.		38

#	Article	IF	Citations
37	VIP hypersecretion as primary or secondary syndrome in neuroblastoma: A retrospective study by the SociÃ©tÃ© FranÃ§aise des Cancers de l'Enfant (SFCE). Pediatric Blood and Cancer, 2009, 52, 585-590.	1.5	36
38	Fanconi anemia and solid malignancies in childhood: A national retrospective study. Pediatric Blood and Cancer, 2015, 62, 463-470.	1.5	36
39	Fineâ€needle aspiration of renal and extrarenal rhabdoid tumors. Cancer Cytopathology, 2011, 119, 49-57.	2.4	33
40	Rubinstein-Taybi syndrome predisposing to non-WNT, non-SHH, group 3 medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 383-386.	1.5	33
41	Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatric Blood and Cancer, 2019, 66, e27641.	1.5	31
42	In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin. Oncogene, 2008, 27, 3066-3071.	5.9	29
43	Non-rhabdoid pediatric SMARCB1-deficient tumors: overlap between chordomas and malignant rhabdoid tumors?. Cancer Genetics, 2014, 207, 384-389.	0.4	29
44	Cholinergic switch associated with morphological differentiation in neuroblastoma. Journal of Pathology, 2009, 219, 463-472.	4.5	26
45	Advancing biology-based therapeutic approaches for atypical teratoid rhabdoid tumors. Neuro-Oncology, 2020, 22, 944-954.	1.2	25
46	Constitutional mismatch repair deficiencyâ€“associated brain tumors: report from the European C4CMMRD consortium. Neuro-Oncology Advances, 2019, 1, vdz033.	0.7	23
47	Conventional Chondrosarcoma in a Survivor of Rhabdoid Tumor. American Journal of Surgical Pathology, 2012, 36, 1892-1896.	3.7	22
48	Does ATRX germline variation predispose to osteosarcoma? Three additional cases of osteosarcoma in two ATR-X syndrome patients. European Journal of Human Genetics, 2018, 26, 1217-1221.	2.8	22
49	Medulloblastomas associated with an APC germline pathogenic variant share the good prognosis of CTNNB1-mutated medulloblastomas. Neuro-Oncology, 2020, 22, 128-138.	1.2	22
50	Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions. Acta Neuropathologica Communications, 2021, 9, 135.	5.2	21
51	Medulloblastomas. Current Opinion in Oncology, 2011, 23, 630-637.	2.4	20
52	Water and Electrolyte Disorders at Long-Term Post-Treatment Follow-Up in Paediatric Patients with Suprasellar Tumours Include Unexpected Persistent Cerebral Salt-Wasting Syndrome. Hormone Research in Paediatrics, 2014, 82, 364-371.	1.8	20
53	Current recommendations for clinical surveillance and genetic testing in rhabdoid tumor predisposition: a report from the SIOPE Host Genome Working Group. Familial Cancer, 2021, 20, 305-316.	1.9	20
54	The EP300:BCOR fusion extends the genetic alteration spectrum defining the new tumoral entity of â€œCNS tumors with BCOR internal tandem duplicationâ€• Acta Neuropathologica Communications, 2020, 8, 178.	5.2	17

#	Article	IF	Citations
55	Imaging Features with Histopathologic Correlation of CNS High-Grade Neuroepithelial Tumors with a BCOR Internal Tandem Duplication. American Journal of Neuroradiology, 2022, 43, 151-156.	2.4	17
56	The extraordinary challenge of treating patients with congenital rhabdoid tumorsâ€"a collaborative European effort. Pediatric Blood and Cancer, 2018, 65, e26999.	1.5	15
57	Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Nonâ€Polyalanine Repeat Expansion Mutations. Pediatric Blood and Cancer, 2016, 63, 71-77.	1.5	14
58	<scp>SMARCA4</scp>â€deficient rhabdoid tumours show intermediate molecular features between <scp>SMARCB1</scp>â€deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type. Journal of Pathology, 2021, 255, 1-15.	4.5	14
59	MYC and MYCN amplification can be reliably assessed by aCGH in medulloblastoma. Cancer Genetics, 2013, 206, 124-129.	0.4	13
60	Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers. Oncotarget, 2017, 8, 34245-34257.	1.8	13
61	SMARCA4-Mutated Atypical Teratoid/Rhabdoid Tumor with Retained BRG1 Expression. Pediatric Blood and Cancer, 2016, 63, 568-569.	1.5	12
62	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
63	Alagille syndrome and nephroblastoma: Unusual coincidence of two rare disorders. Pediatric Blood and Cancer, 2008, 50, 908-911.	1.5	11
64	A CBF decrease in the left supplementary motor areas: New insight into postoperative pediatric cerebellar mutism syndrome using arterial spin labeling perfusion MRI. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 3339-3349.	4.3	10
65	Intraâ€•and extraâ€cranial <scp>BCORâ€ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	3.0	10
66	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, 42, 781-794.	3.8	10
67	Deep intronic hotspot variant explaining rhabdoid tumor predisposition syndrome in two patients with atypical teratoid and rhabdoid tumor. European Journal of Human Genetics, 2017, 25, 1170-1172.	2.8	8
68	ATRT-11. MARKED RESPONSE TO ATEZOLIZUMAB IN AÂPATIENT WITH RHABDOID TUMOR: AÂCASE STUDY FROM THE IMATRIX-ATEZOLIZUMAB TRIAL. Neuro-Oncology, 2017, 19, iv3-iv3.	1.2	8
69	Metastatic neuroblastoma in a patient with ROHHAD: A new alert regarding the risk of aggressive malignancies in this rare condition. Pediatric Blood and Cancer, 2019, 66, e27906.	1.5	8
70	Focal Areas of High Signal Intensity in Children with Neurofibromatosis Type 1: Expected Evolution on MRI. American Journal of Neuroradiology, 2020, 41, 1733-1739.	2.4	8
71	Immune responses in genomically simple SWI/SNFâ€"deficient cancers. Cancer, 2021, 127, 172-180.	4.1	7
72	Extracranial rhabdoid tumours: Results of a SFCE series of patients treated with a dose compression strategy according to European Paediatric Soft tissue sarcoma Study Group recommendations. European Journal of Cancer, 2022, 161, 64-78.	2.8	7

#	Article	IF	Citations
73	The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients. Journal of Neuro-Oncology, 2022, 157, 355-364.	2.9	7
74	Les Ã©motions dans la relation de soin : des racines de leur rÃ©pression aux enjeux de leur expression. Ã‰thique & SantÃ©, 2006, 3, 133-137.	0.1	6
75	Clinical, pathological, and molecular data on desmoplastic/nodular medulloblastoma: case studies and a review of the literature. , 2016, 35, 106-113.		6
76	Enrollment in earlyâ€phase clinical trials in pediatric oncology: The experience at Institut Curie. Pediatric Blood and Cancer, 2018, 65, e26916.	1.5	6
77	Rare germline heterozygous missense variants in BRCA1-associated protein 1, BAP1, cause a syndromic neurodevelopmental disorder. American Journal of Human Genetics, 2022, 109, 361-372.	6.2	6
78	High Prevalence of Early Endocrine Disorders After Childhood Brain Tumors in a Large Cohort. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e2156-e2166.	3.6	6
79	Germline mutations in FGF receptors and medulloblastomas. American Journal of Medical Genetics, Part A, 2013, 161, 382-385.	1.2	5
80	Congenital Disseminated Extrarenal Malignant Rhabdoid Tumor. Pediatric and Developmental Pathology, 2015, 18, 401-404.	1.0	4
81	Rhabdoid component emerging as a subclonal evolution of paediatric glioneuronal tumours. Neuropathology and Applied Neurobiology, 2018, 44, 224-228.	3.2	4
82	SHH medulloblastoma in a young adult with a TCF4 germline pathogenic variation. Acta Neuropathologica, 2019, 137, 675-678.	7.7	4
83	Homozygous PTEN deletion in neuroblastoma arising in a child with Cowden syndrome. American Journal of Medical Genetics, Part A, 2011, 155, 1763-1766.	1.2	3
84	A novel case of cribriform neuroepithelial tumor: A potential diagnostic pitfall in the ventricular system. Pediatric Blood and Cancer, 2021, 68, e29037.	1.5	3
85	Droit de savoir â€“ droit Ã lâ€™ignorance, aspects Ã©thiques et psychologiques en oncogÃ©nÃ©tique pÃ©diatrique. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2015, 3, 116-122.	0.1	2
86	Genetic predisposition to medulloblastomas: just follow the tumour genome. Lancet Oncology, The, 2018, 19, 722-723.	10.7	2
87	NSRG-05. SAFETY OF ULTRASOUND-INDUCED BLOOD-BRAIN BARRIER OPENING IN PEDIATRIC PATIENTS WITH REFRACTORY SUS-TENTORIAL MALIGNANT BRAIN TUMORS BEFORE CHEMOTHERAPY ADMINISTRATION â€“ THE SONOKID CLINICAL TRIAL. Neuro-Oncology, 2018, 20, i146-i146.	1.2	2
88	Are B7-H3 CAR-T cells the future universal treatment for pediatric brain tumors?. Neuro-Oncology, 2021, 23, 872-873.	1.2	2
89	A SMARCB1-Deficient, Highly Penetrant Brain Tumour Mouse Model Recapitulates Human AT/RT. Cancer Genetics, 2014, 207, 451.	0.4	1
90	Rhabdoid Tumours of Brain, Liver, Kidney and Soft-Parts: Expression Profiles Suggest Common Features but Different Entities.. Cancer Genetics, 2014, 207, 448.	0.4	1

#	Article	IF	Citations
91	Tumeur et dÃ©veloppement (TED)Â: un enregistrement national des associations de cancers pÃ©diatriques et de pathologies malformatives. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2014, 2, 70-77.	0.1	1
92	A malignant choroid plexus tumour with prevailing immature blastematous elements. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	1
93	Chromosomes en puzzle, le chromothripsis. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2013, 1, 41-43.	0.1	0
94	Right to know and right to ignore in paediatric oncogenetics: Identifying biological causes, or seeking for meaning?. European Journal of Cancer, 2016, 63, 53-54.	2.8	0
95	MBCL-38. MEDULLOBLASTOMAS ASSOCIATED WITH APC GERMLINE MUTATION: A MULTICENTRIC FRENCH AND BELGIAN REVIEW. Neuro-Oncology, 2018, 20, i125-i125.	1.2	0
96	High-grade childhood intra-parenchymal brain tumor clustering with ATRT and expanding the cancer spectrum related to inherited SMARCE1 truncating variations. Acta Neuropathologica Communications, 2022, 10, 24.	5.2	0